JPRN-UMIN000003472已完成2 期
Bortezomib with Dexamethasone compared with oral melphalan and predonisone pluse bortezomib in patients with refractory multiple myeloma: randomized phase 2 study - PhaseII trial of bortezomib based regimen for multiple myeloma refractory to melphalan-predonine (MP) therapy-Tohoku Myeloma Treatment Organization TOMATO Study
Deparment of Hematology&Rheumatology, Tohoku University Hospital0 个研究点目标入组 32 人开始时间: 2010年4月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.History of allergic reactions attributed to compounds described in this protocol. 2.History of allergic reaction attributed to bortezomib, mannitol, boron. 3.Active systemic infections requiring treatment. 4.Serious psychiatric illness. 5.Serious respiratory diseases or dysfunction. 6.Suspected with interstitial pneumonia by chest X-P or CT scan. 7.Serious cardiac dysfunction or required treatment. 8.Required hemodialysis not attribute to myeloma. 9.With plasma cell leukemia. 10.Pregnant or lactating. 11.ositive for HBs antigen, HCV antibody, or HIV antibody. 12.Otherwise judged by investigator to be unsuitable.
研究者
相似试验
进行中（未招募）
不适用
Bortezomib and dexamethasone treatment before donor lymphocyte infusions for myeloma patients progressing or relapsing after allogeneic transplantation of hematopoietic cells - NDMyeloma patients progressing or relapsing after allogeneic transplantationMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-004815-24-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI40
已完成
2 期
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseMultiple MyelomaACTRN12606000180516Peter MacCallum Cancer Centre100
进行中（未招募）
不适用
Phase II Study of combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom?s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - NDWaldenstrom macroglobulinemiaMedDRA version: 9.1Level: LLTClassification code 10047714Term: Von Waldenstrom macroglobulinaemiaEUCTR2006-003563-31-ITE.M.N. - EUROPEAN MYELOMA NETWORK61
招募中
2 期
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma Networkimmunocytomalymphoplasmacytic lymphomaWaldenstroms Macroglobulinemia10018865NL-OMON30654Academisch Medisch Centrum5
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - protocole BDRMacroglobulinémie de Waldenström au moment de l’initiation du traitement de 1e ligne.EUCTR2006-003563-31-FRCentre Hospitalier de Lens61